About Lysophosphatidic acid phosphatase type 6
Lysophosphatidic acid phosphatase type 6 (ACP6) is a protein
from Homo sapiens identified by UniProt accession
Q9NPH0, 428 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Lysophosphatidic acid phosphatase type 6 |
| UniProt accession | Q9NPH0 |
| Gene | ACP6 |
| Organism | Homo sapiens |
| Length | 428 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.36
- body height · score 0.34
- Rare genetic intellectual disability with developmental anomaly · score 0.27
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.18
- granulocyte count · score 0.16
- hepatocellular carcinoma · score 0.07
- response to fenofibrate · score 0.07
- triglyceride change measurement · score 0.07
- response to simvastatin · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NPH0-F1 | alphafold | PREDICTED | 90.90 | — |
Amino-acid sequence (428 residues)
MITGVFSMRL WTPVGVLTSL AYCLHQRRVA LAELQEADGQ CPVDRSLLKL KMVQVVFRHG ARSPLKPLPL EEQVEWNPQL LEVPPQTQFD YTVTNLAGGP KPYSPYDSQY HETTLKGGMF AGQLTKVGMQ QMFALGERLR KNYVEDIPFL SPTFNPQEVF IRSTNIFRNL ESTRCLLAGL FQCQKEGPII IHTDEADSEV LYPNYQSCWS LRQRTRGRRQ TASLQPGISE DLKKVKDRMG IDSSDKVDFF ILLDNVAAEQ AHNLPSCPML KRFARMIEQR AVDTSLYILP KEDRESLQMA VGPFLHILES NLLKAMDSAT APDKIRKLYL YAAHDVTFIP LLMTLGIFDH KWPPFAVDLT MELYQHLESK EWFVQLYYHG KEQVPRGCPD GLCPLDMFLN AMSVYTLSPE KYHALCSQTQ VMEVGNEE
Explore Lysophosphatidic acid phosphatase type 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets